Press Releases Latest Nov 24, 2023 Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award Press Releases Year None20232022202120202019201820172016201520142013 Jul 28, 2023 Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management Jul 21, 2023 Theratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn Jul 20, 2023 Theratechnologies Announces 1-for-4 Reverse Stock Split Jul 12, 2023 Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates Jun 29, 2023 Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update Jun 22, 2023 Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management Jun 12, 2023 Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial Jun 02, 2023 Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide May 25, 2023 Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023 May 09, 2023 Theratechnologies Reports on its Annual Meeting of Shareholders First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 21 - 30 of 339
Jul 28, 2023 Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management
Jul 21, 2023 Theratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn
Jun 29, 2023 Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update
Jun 22, 2023 Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management
Jun 12, 2023 Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial
Jun 02, 2023 Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
May 25, 2023 Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
